Weight-Loss Drug Race Shifts: Eli Lilly Gains Momentum as Novo Nordisk Faces Headwinds
While Novo Nordisk pioneered the blockbuster GLP-1 market with Ozempic, Eli Lilly's latest earnings reveal a company pulling ahead in the battle for long-term dominance, fueled by soaring demand for Mounjaro and Zepbound.